Novartis, a leading Swiss pharmaceutical company, has received approval from the Food and Drug Administration (FDA) to manufacture its Pluvicto radioligand therapy at its new facility in Indianapolis. This expansion comes as a response to the increasing demand for cancer treatments in North America.
Meeting Growing Demand
Novartis’ latest FDA approval is set to significantly boost the production capacity of radioligand therapy, allowing for up to 250,000 doses to be produced in 2024 and beyond. With existing facilities in New Jersey, Italy, and Spain, the addition of a second US facility in Indianapolis marks a significant milestone for the company.
Commitment to Patient Care
Steffen Lang, President of Operations at Novartis, emphasized the company’s commitment to providing a consistent and reliable experience for patients and their healthcare teams. The newly established Indianapolis facility, described as their largest and most advanced facility to date, reaffirms Novartis’ dedication to meeting the needs of patients now and in the future.
Expanding Worldwide Reach
In addition to the expansion in Indianapolis, Novartis has recently announced plans to strengthen its manufacturing capabilities in Sasayama, Japan, and Haiyan, Zhejiang, China. These strategic moves demonstrate Novartis’ proactive approach to expanding its global presence and ensuring that their life-saving therapies reach patients worldwide.
